Study guide

5.2 Device Instructions, Configuration and Training

ACRP CCRA Certified Clinical Research Associate Study Guide 2026 Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Format, Eligibility and Registration

1.1 Exam Format, Eligibility and Current References 1.2 Registration, Fees and Candidate Decisions

2 Chapter 2: CRA Responsibilities and Study Planning

2.1 The CRA Role, Data Integrity and Product Oversight 2.2 Official Blueprint and Study Strategy

3 Chapter 3: Protocols, Endpoints and Trial Design

3.1 Protocol Elements and Endpoint Hierarchy 3.2 Endpoint Interpretation and Eligibility Rationale 3.3 Eligibility Verification and Trial Designs

4 Chapter 4: Bias Control, Blinding and Product Information

4.1 Bias, Randomisation and Comparator Controls 4.2 Unblinding and Investigator Brochure Content 4.3 Reference Safety Information and IB Updates

5 Chapter 5: Estimands and Device Instructions

5.1 Estimands and Intercurrent Events 5.2 Device Instructions, Configuration and Training

6 Chapter 6: Ethical Foundations and Independent Oversight

6.1 Ethical Foundations and the 2024 Declaration of Helsinki 6.2 Vulnerability, Voluntariness and Compensation 6.3 IRB/IEC Composition and Independent Review

7 Chapter 7: Ethics Communication and Informed Consent

7.1 Ethics Reporting, Approval Status and Version Control 7.2 Informed Consent Information and Meaningful Choice 7.3 Consent Documentation, Special Circumstances and Updates

8 Chapter 8: Recruitment, Retention and Confidentiality

8.1 Ethical Eligibility, Recruitment and Retention 8.2 Privacy, Confidentiality and Appropriate Access

9 Chapter 9: Safety Definitions and Classification

9.1 Adverse Event Definitions and Actual Life-Threatening Risk 9.2 Seriousness, Severity and Medical Importance 9.3 Causality, Expectedness and Reference Safety Information

10 Chapter 10: Safety Detection, Reporting and Oversight

10.1 Detecting Events, AESIs and Collection Windows 10.2 Expedited Reporting and the Sponsor Awareness Clock 10.3 Immediate Site Reporting and Independent Safety Oversight

11 Chapter 11: Follow-Up, Adherence and Conflicts

11.1 Safety Communications, Reconciliation and Follow-Up 11.2 Adherence, Discontinuation and Participant Choice 11.3 Conflicts of Interest and Prorated Payments

12 Chapter 12: Development Stages and Product Management

12.1 Nonclinical Background and Human Pharmacology 12.2 Exploratory, Confirmatory and Therapeutic-Use Studies 12.3 Product Storage, Labelling and Excursion Response

13 Chapter 13: Accountability, Integrity and Regulatory Status

13.1 Product Accountability and Adherence Calculations 13.2 Potential Fraud, Misconduct and Evidence Preservation 13.3 Submissions, Authorisation Status and Trial Reporting

14 Chapter 14: Current GCP Principles and Delegation

14.1 The Eleven Current GCP Principles 14.2 Proportionality and Investigator Oversight 14.3 Delegation, Qualifications and Task Authority

15 Chapter 15: Oversight, Protocol Control and Amendments

15.1 Clinical Oversight and Immediate-Hazard Changes 15.2 Deviation Classification and Resolution

16 Chapter 16: Implementation and Trial Responsibilities

16.1 Amendment Implementation and Communication 16.2 Sponsor, Investigator and Service-Provider Roles

17 Chapter 17: Quality Planning, Root Causes and CAPA

17.1 Quality Planning and Risk Management 17.2 Root Cause Analysis and CAPA Design 17.3 CAPA Implementation and Effectiveness Verification

18 Chapter 18: Risk Assessment and Monitoring Methods

18.1 Risk Assessment and Centralised Surveillance 18.2 Monitoring Methods and Source Review

19 Chapter 19: Quality Metrics, Plans and Communication

19.1 KRIs, Acceptable Ranges and Trial-Level Quality 19.2 Monitoring Plans, Co-Monitoring and Communication

20 Chapter 20: Site Qualification and Readiness

20.1 Site Qualification and Investigator Capacity 20.2 Recruitment Feasibility and Evidence-Based Site Selection 20.3 Site Readiness and Activity-Specific Release

21 Chapter 21: Initiation, Equipment and Supplies

21.1 Initiation Training and Readiness Walkthroughs 21.2 Equipment, Maintenance and Study Supplies

22 Chapter 22: Samples, Diagnostics and Financial Feasibility

22.1 Specimens, Diagnostic Results and Rater Quality 22.2 Contracts, Budgets and Operational Feasibility

23 Chapter 23: Interim Monitoring and Reporting

23.1 Interim Visit Preparation and Consent Review 23.2 Monitoring Eligibility, Safety and Products 23.3 Investigator Debrief and Monitoring Reports

24 Chapter 24: Essential Records, Audits and Findings

24.1 Essential Records and Site/Sponsor Reconciliation 24.2 Version History, Resolution Evidence and Noncompliance 24.3 Audits, Inspections and Closure Planning

25 Chapter 25: Close-Out, Retention and Destruction

25.1 Close-Out, Archiving and Continuing Obligations 25.2 Retention, Destruction and Long-Term Access

26 Chapter 26: Source Records and Good Documentation

26.1 Source Records and Foundational ALCOA Principles 26.2 Good Documentation, Completeness and Corrections 26.3 Source Access, Certified Copies and Context

27 Chapter 27: Electronic Systems, Metadata and Queries

27.1 EDC Design and Fit-for-Purpose Systems 27.2 Audit Trails, Electronic Outcomes and Device Choice 27.3 Queries, Coding and Supported Clinical Meaning

28 Chapter 28: Dataset Finalisation and Critical Data

28.1 Safety Reconciliation and Dataset Finalisation 28.2 Critical Data, Acquisition Tools and Interim Findings

5.2 Device Instructions, Configuration and Training

Key Takeaways Explain This Topic AI

Device instructions and configuration should match the product used in the trial.

Operator competence is task-specific and cannot be inferred from general GCP training alone.

A malfunction can need documented assessment even when intervention prevented injury.

Last updated: October 2026

Device Instructions, Configuration and Training

The CCRA ECO explicitly includes the Investigator's Brochure and investigational-device instructions for use. The common skill is translating current product information into safe, reproducible trial conduct. A brochure stored in a binder is insufficient if staff use a different model, obsolete instructions or a configuration that does not match the protocol. Review the product's identity, version, intended trial use and required preparation before evaluating apparent compliance.

For a medicinal product, the IB summarises relevant nonclinical and clinical experience and provides guidance for investigators. For a device, instructions may specify setup, configuration, operation, precautions and handling. Do not assume that an investigational device uses the drug-development phase labels or that ICH supplies every device-specific technical requirement. The trial protocol, applicable product instructions and requirements define the actual activity.

A document-to-practice verification chain

Identify the product/model, formulation or configuration used by the site.

Confirm the current applicable protocol and product-information version.

Verify who performs the task and their relevant training or certification.

Observe or review evidence of the actual workflow, within authorised monitoring scope.

Compare the resulting records, product traceability and any reported problems.

Escalate mismatches and preserve the evidence supporting the assessment.

A product update can affect several controls at once. A new setup instruction may require staff training and a revised checklist. A newly identified risk can require urgent communication, protocol evaluation and updated consent. A revised storage instruction can affect shipping and pharmacy records. The monitor should trace these consequences rather than merely obtaining a receipt signature.

Model and software configuration

Suppose the study uses a diagnostic device with a specified software algorithm. A site installs a newer commercial software release because it appears to improve performance. Even if the display looks familiar, the change could affect endpoint calculation, data format, compatibility or calibration. Identify the installed version, when the change occurred and affected assessments. Notify the sponsor's responsible technical/clinical function and follow the controlled evaluation process.

Do not tell staff to uninstall the software immediately without considering clinical safety and data preservation. Retain configuration and change records, original outputs and relevant metadata. The sponsor needs to assess comparability, participant impact, whether repeat assessments are appropriate and whether any amendment or reporting is needed. Repeating a measurement later cannot recreate the original time point.

Operator training and competency

Training should address the activity the person actually performs. Reading a general GCP certificate does not establish competence to operate a specialised device or score an imaging outcome. Verify required task training, a usable instruction set and access to technical support. If the protocol requires rater or operator certification, establish that it was current before the affected assessments and determine how staff turnover is managed.

A training log can document attendance while leaving understanding uncertain. A practical demonstration, supervised run or review of initial outputs may be appropriate to the task. The monitor does not invent a universal competency exam; they verify the plan and escalate evidence that it does not control a critical process adequately. Confirm that delegated personnel understand how to recognise and communicate a malfunction or clinically significant result.

Traceability and problems without injury

Track the identifiers required by the trial: model, batch, serial number, kit or configuration, use dates and participant code as relevant. Not every study uses the same identifier scheme. The purpose is to reconstruct which participant encountered which product and to act on a defect, recall or safety concern. Keep unused, returned, damaged and used supplies distinguishable.

A malfunction or use error can matter even when the participant was unharmed. A clinician's successful intervention may have prevented an adverse outcome. Document the facts and clinical assessment, use the trial's escalation process and preserve relevant product evidence. Do not assign a universal national device classification or reporting deadline from a generic vignette. Do not clean, discard or modify a retrieved product contrary to the investigation instructions.

A monitoring scenario

A device-use log lists model A for a participant, while the procedure record lists model B. The operator says the two are equivalent. The CRA should examine shipment/accountability records, packaging identifiers, procedure evidence and configuration history, then seek qualified clarification. If model B was used, determine whether it was permitted and evaluate the impact through the sponsor and investigator. If the log contains a transcription error, correct it traceably with supporting evidence.

Both routes preserve the original entry and the reason for correction. Neither involves changing every record to the model that would make the case compliant. This is the same reasoning used for an IB update or a medicinal-product kit discrepancy: identify the applicable instructions, establish what happened, protect participants, and document the evaluated response.

Official sources

Checked October 18, 2026: ICH E6(R3), Principles and Annex 1 , ICH E9 , ICH E9(R1) , ICH E8(R1) .